WRAL Tech Wire

GSK pays $99M to absorb UK-based drug tech firm

The drug giant will assume control of Cellzome in which it already held a 20 percent ownership stake. The deal is GSK's third involving drug platform technology since 2007.

GSK secures approval for new acne treatment

Tazarotene, which will be marketed under the name Fabior Foam, is a topical foam developed to treat acne vulgaris. It was developed by GSK subsidiary Stiefel Laboratories, the dermatology products company that GSK acquired in 2009

GSK makes $2.6B takeover bid for Human Genome Sciences

GlaxoSmithKline said Wednesday it will take its $2.6 billion bid for Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the U.S. biotech group's board.

GSK's CEO says no to AstraZeneca, still wants Human Genome Sciences

At GlaxoSmithKline's annual meeting, Andew Witty says no to idea of acquiring AstrraZeneca but also defends GSK's $2.6 billion bid for Human Genome Sciences.

GSK strikes drug development deal with Yale

The collaboration will build on Yale's research into ways to break down disease-causing proteins. The technology, called proteolysis-targeting chimeric molecules or PROTACs, leads disease-causing proteins to the part of a cell where they can be destroyed.

Big Human Genome shareholder calls GSK takeover offer a 'steal'

GlaxoSmithKline is offering $13 a share for Human Genome, but a representative for Taube Hodson and Sontex says even a $20 bid would feel "undervalued." GSK has defended its offer.

GSK meningitis vaccine wins European approval

Infants and toddlers up 4-years-old are at greatest risk of developing meningitis from this bacteria. The contagious disease can lead to deafness, epilepsy and neurological disorders. Severe cases can be fatal.

GSK wins approval for wider use of kidney cancer drug

The approval means that patients who have advanced soft tissue sarcoma will now have access to the first new treatment in decades.

GSK's CEO refuses to give up on acquiring Human Genome Sciences

"We absolutely believe that we are the compelling owner for this business," Andrew Witty. "We have the rights and the operational control for the three main assets and we believe this is the right time to maximize value for both sets of shareholders."

Andrew Witty

Revenue is up, U.S. sales surge but profits decline for GSK

GlaxoSmithKline reports 9 percent surger in U.S. sales and an overall 1 percent increase in revenue but a drop of 13 percent in earnings for the first quarter.

Human Genome rejects GSK's $2.59B takeover bid

Human Genome Sciences rejected an unsolicited takeover bid on Thursday by GlaxoSmithKline.

GSK looks to Japan for possible cancer breakthroughs

GlaxoSmithKline is working with Chrome Bioscience, a Japanese biotechnology company, to see if that company's technology can find potential new cancer treatments.

Chrome Bioscience diagrams its research

Cree cuts streetlight price; Red Hat's storage beta and data platform; GSK cuts vaccine price; Ciso CEO goes on attack

Inside the Bulldog blog: Cree is cutting LED streetlight prices in half; Red Hat unveils a storage solution beta plus an open source data platform; GSK and Merck are discounting vaccines to combat diarrhea; Cisco's John Chambers aims attack at Chinese rival.

Virus targets Macs; iPad WiFi issues; Lenovo Smart TV launch; GSK HPV drug discount; Nortel trial

Inside the Bulldog Blog: Hackers reportedly hit Macs; iPad WiFi issue draws Apple attention; Lenovo preparing for Smart TV orders; GSK, Merck talking discounts for HPV virus drugs; Nortel execs acted in good faith, trial told.

GSK to move ahead with experimental diabetes drug

The proposed once-weekly injectable albiglutide would offer a dosing advantage to the once-daily Novo Nordisk injectable drug Victoza.